Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194111 · ClinicalTrials.gov registry record · Phase 1
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
A Phase 1 study of Heart Failure and Heart Dysfunction, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT05194111: Recruiting Phase 1 study of Heart Failure and Heart Dysfunction, sponsored by Virginia Commonwealth University.
NCT05194111 is a Phase 1 study of Heart Failure and Heart Dysfunction that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 53 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05194111, a Phase 1 study of Heart Failure and Heart Dysfunction, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
Primary Outcome
Number of participants screened for the clinical trial.
Conditions Studied
Interventions
- DRUG Sacubitril-valsartan
- DRUG Valsartan
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 1 |
What NCT05194111 shows while recruiting
NCT05194111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Sacubitril-valsartan is the first listed.
NCT05194111 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05194111 about?
NCT05194111 is a clinical study titled "Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan". To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
What is the current status of trial NCT05194111?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2022-08-11. Estimated completion is 2028-11-30.
What conditions does trial NCT05194111 study?
This clinical trial studies the following conditions: Heart Failure, Heart Dysfunction.
What interventions are being tested in trial NCT05194111?
The interventions under investigation include: Sacubitril-valsartan (DRUG), Valsartan (DRUG).
Who is sponsoring clinical trial NCT05194111?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05194111 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05194111's enrollment target sits among peer trials
53 277th of 397 higher than 119 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Semaglutide Therapy in Heart Failure Patients
RECRUITING · Phase 1
-
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 3
RECRUITING · Phase 1
-
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
RECRUITING · Phase 1
-
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
RECRUITING · Phase 1
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI